1、novotech-OCTOBER 27,2023Metastatic Breast Cancer-Global Clinical Trial Landscape(2023)APAC contributed 35%of MBC trials,led by Mainland China,South Korea,and AustraliaThe US and Europe conducted 50%of MBC trials,with Spain and France in the leadROW conducted roughly 10%of the global MBC trialsAPAC s

2、hows shorter recruitment durations and faster recruitment rates compared to Europe and the US50%10%35%In Asia,there were over 0.3 million estimated cases of MBC,with Mainland China,India,and Japan collectively contributing over 30%of the global MBC incidenceThe US and Europe together comprise around

3、 35%of MBC casesROW(including the Middle East,Africa,and South and Central America),accounted for approximately 20%of the global MBC incidenceMBC occurs when breast cancer cells spread to other parts of the bodyMBC comprises 20-30%of all breast cancer casesTrastuzumab biosimilar(trastuzumab-dttb)wit

4、h the brand name Ontruzant is marketed in multiple countries,including the United States,Canada,New Zealand,Spain,and GermanyDisitamab Vedotin is currently in Phase III clinical trials for MBC in China,showing promise as a potential treatment option in developmentIn 2020,global MBCincidence exceeded

5、 NSCLCGLOBAL CLINICAL TRIAL LANDSCAPE The content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other electronic or mechanical methods,without the

6、 prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech.Any